Amgen Opposes Review Of Commercial Marketing Notice To Product Sponsor

(November 17, 2016, 5:53 PM EST) -- WASHINGTON, D.C. — Amgen Inc. and Amgen Manufacturing Ltd. (collectively, Amgen) argue in a Nov. 8 opposition brief that the U.S. Supreme Court should decline to review whether the Federal Circuit...
To view the full article, register now.